REG - Oxford Biomedica PLC - OXB completes acquisition of US subsidiary

Oxford BioMedicaAnnouncement

23/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250623:nRSW8943Na&default-theme=true

RNS Number : 8943N  Oxford Biomedica PLC  23 June 2025

 

 

OXB completes acquisition of remaining stake in

US subsidiary

 

Progression to full ownership aligns with global strategy and supports
long-term growth in the viral vector manufacturing market

 

Oxford, UK - 23 June 2025: OXB (LSE: OXB) ("the Company"), a global quality
and innovation-led cell and gene therapy CDMO, today announces that it has
acquired the remaining 10% stake in its US subsidiary from Q32 Bio, Inc.
(Q32), bringing its ownership, as planned, to 100%.

 

As previously disclosed in the Company's Preliminary Results
(https://otp.investis.com/clients/uk/oxford_biomed1/rns/regulatory-story.aspx?cid=544&newsid=1927065)
on 9 April 2025, OXB US Inc., OXB's wholly owned US subsidiary, exercised its
call option on 1 March 2025 to acquire the final 10% interest in OXB US LLC
from Q32. The stake was originally held by Homology Medicines, Inc (Homology),
which merged with Q32 in 2024. The transfer of Q32's 10% holding to OXB US
Inc., means that OXB US LLC is now wholly owned by OXB.

 

OXB US LLC was originally established in Bedford, MA, in 2022, as an AAV
manufacturing and innovation business. The facility has since been fully
integrated into OXB's global network, successfully completing the tech
transfer of its lentiviral platform to the site in 2024. Spanning
96,000 ft², the site offers lentiviral and AAV vector capabilities and has
supported the onboarding of multiple new programmes in the US, as part of
OXB's global cell and gene therapy development and manufacturing network.

 

Dr Frank Mathias, Chief Executive Officer of OXB, commented: "The progression
to full ownership of our US business marks an important step for OXB. It
strengthens our position in a key market and helps meet growing demand for
high-quality vector manufacturing - a critical enabler of the expanding cell
and gene therapy market.

"Our presence in the US, alongside our existing sites in the UK and France,
gives clients access to deep expertise across AAV and lentiviral-based
therapies. Through OXB's network, we are able to support clients globally
across all key vector types - from early-stage development through to
commercialisation."

 

-Ends-

 

Enquiries:

 

OXB:

Sophia Bolhassan, Head of Investor Relations - T: +44 (0) 1865 509 737 / E:
ir@oxb.com (mailto:ir@oxb.com)

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class capabilities range
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

OXB offers a vast number of unique technologies for viral vector
manufacturing, including a 4th generation lentiviral vector system (the
TetraVecta™ system), a dual-plasmid system for AAV production, suspension
and perfusion process using process enhancers and stable producer and
packaging cell lines.

 

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has
development and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France and Bedford MA, US. Learn more at www.oxb.com
(http://www.oxb.com) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPKBBBOBKDOAB